Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 19Gynecologic 3Genitourinary 3Breast 3Thoracic 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Small Cell Lung Carcinoma 52Neoplasms 8Melanoma 8Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Mesothelioma, Malignant 6Mesothelioma 6Colorectal Neoplasms 6Carcinoma 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Respiratory Tract Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Diseases 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Bronchogenic 3Bronchial Neoplasms 3Adenocarcinoma of Lung 3

Interventions

pembrolizumab 34Cisplatin 12Nivolumab 10atezolizumab 9Docetaxel 9Carboplatin 9Paclitaxel 8Cetuximab 8Gemcitabine 7Blood Specimen Collection 7Radiotherapy 6Fluorouracil 6Drug Therapy 6cemiplimab 5Pemetrexed 5Immune Checkpoint Inhibitors 5fludarabine 4Standard of Care 4Cyclophosphamide 4spartalizumab 3epacadostat 3Surveys and Questionnaires 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Interleukin-2 3Filgrastim 3Bupropion 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × durvalumab × Thoracic × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02318277 2022-01-13

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Incyte Corporation

Phase 1/2 Completed
176 enrolled 25 charts
Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡